Thursday 16 October, 2025
Objectives: The adequate characterization of the tumor dynamics is crucial to understand cancer progression and response to treatment. In this…
Read morePoster: Drug/Disease Modelling - Oncology
Non linear mixed effects modelling of tumour interactions with the adaptive immune response during Radiotherapy in combination with anti-PDL1 or Olaparib.
Thursday 16 October, 2025
Objectives: Preclinical studies have shown that that it is possible to synergistically increase the efficacy of radiotherapy (RT) using additional…
Read moreThe multivariate baseline and longitudinal biomarker analysis for the survival prediction in NSCLC by means of joint modeling
Thursday 16 October, 2025
Objectives: Tumor size is a validated surrogate biomarker for assessment of treatment efficiency and survival in patients with non-small cell lung…
Read moreSemi-mechanistic model for the antitumor response of a combination cocktail of immune-modulators in non-inflamed (cold tumors)
Thursday 16 October, 2025
Objectives: Immune checkpoint inhibitors administered as single agent have demonstrated clinical efficacy in certain tumor types [1,2]. However, when treating…
Read moreDose dependence of safety of PD-1 and CTLA-4 checkpoint inhibitors: Comparison of normal-normal and binomial-normal hierarchical models for rare events in a Bayesian meta-analysis framework
Thursday 16 October, 2025
Introduction: Immune checkpoint inhibitors (ICIs) are promising anti-cancer therapies; yet, they are associated with immune-mediated adverse events (imAE), especially in…
Read moreCachexia-associated anticancer drug toxicity is minimally mediated by alteration of drug’s pharmacokinetics: Erlotinib as case study
Thursday 16 October, 2025
Introduction Cachexia is an irreversible condition of muscle mass loss characterised by chronic systemic inflammation and energy imbalance. It commonly…
Read moreComputational analysis of cytokine release following bispecific T-cell engager therapy
Thursday 16 October, 2025
Introduction: Bispecific T cell Engager (BiTE®) molecules offer a promising treatment that uses the patient’s own immune system towards eliminating…
Read moreApplying a quantitative system pharmacology (QSP) model to inform KRASG12C covalent inhibitors’ PK driver level needed for efficacy in patients with non-small cell lung cancer (NSCLC)
Thursday 16 October, 2025
Introduction: KRAS mutation occur in 30% of all human cancers [1], however, this target is known to be undruggable until…
Read moreRituximab PK and PD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarity
Thursday 16 October, 2025
Objectives: Addition of rituximab to the standard-of-care chemotherapy cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) leads to significant improvement in the long-term…
Read moreApplication of physiologically-based pharmacokinetic model to mechanistically predict increased tumour uptake of paclitaxel in cancer patients
Thursday 16 October, 2025
Objectives: Tubulin targeting drugs such as paclitaxel exert their effect intracellularly within tumor, thus sufficient intracellular drug concentrations are essential…
Read more